Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa

Much Ground To Make Up On J&J's Darzalex

Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.

Sanofi_France
Sanofi highlighted Sarclisa at virtual oncology briefing • Source: Shutterstock

Boosted by European approval and promising fresh data for Sarclisa, Sanofi has been talking up the prospects for its multiple myeloma drug as the treatment of choice among CD38-targeting therapies and challenging Johnson & Johnson’s blockbuster Darzalex.

The French major put Sarclisa (isatuximab) in the spotlight at its cancer strategy and progress update following the American Society...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category